MRTX:NSC-Mirati Therapeutics Inc.

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing

USD 62.47

Change

-2.33 (-3.60)%

Market Cap

USD 0.11B

Volume

0.83M

Analyst Target

USD 64.88
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Mirati Therapeutics Inc is a biopharmaceutical company that discovers, develops, and commercializes novel therapeutics with an initial focus on cancer and infectious diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+5.64 (+1.43%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

+3.34 (+0.37%)

USD 106.98B
MRNA Moderna Inc

+3.05 (+3.01%)

USD 38.83B
BNTX BioNTech SE

+1.20 (+1.38%)

USD 21.93B
ARGX argenx NV ADR

+8.52 (+2.37%)

USD 21.70B
GMAB Genmab AS

+0.27 (+0.94%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

+1.38 (+0.96%)

USD 18.26B
RPRX Royalty Pharma Plc

-0.34 (-1.21%)

USD 18.18B
BGNE BeiGene Ltd

+1.42 (+1.10%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

+0.86 (+0.97%)

USD 16.06B

ETFs Containing MRTX

DWAQ 0.00 % 0.60 %

N/A

N/A
CHNA 0.00 % 0.62 %

N/A

N/A
CHNA 0.00 % 0.79 %

N/A

N/A
WRNA:XETRA WisdomTree BioRevolution .. 0.00 % 0.00 %

N/A

USD 2.77M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 47.27% 94% A 97% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 47.27% 94% A 97% N/A
Trailing 12 Months  
Capital Gain 157.61% 97% N/A 98% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 157.61% 97% N/A 98% N/A
Trailing 5 Years  
Capital Gain 187.22% 88% B+ 93% A
Dividend Return N/A N/A N/A N/A F
Total Return 187.22% 88% B+ 93% A
Average Annual (5 Year Horizon)  
Capital Gain 161.44% 97% N/A 99% N/A
Dividend Return 161.44% 97% N/A 99% N/A
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 346.27% 3% F 1% F
Risk Adjusted Return 46.62% 81% B- 58% F
Market Capitalization 0.11B 89% A- 81% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -21.10 92% 89%
Price/Book Ratio 8.24 15% 11%
Price / Cash Flow Ratio -7.30 92% 93%
Price/Free Cash Flow Ratio -30.77 93% 92%
Management Effectiveness  
Return on Equity -46.90% 58% 21%
Return on Invested Capital -48.47% 55% 21%
Return on Assets -42.79% 54% 16%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector